Larimar Therapeutics Inc (LRMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $311.65M
Last updated: Nov 17, 2026 at 4:15 PM ET
Larimar Therapeutics Inc (LRMR) Statistics
Larimar Therapeutics (LRMR) has a market cap of $311.65M and an enterprise value of $234.66M. Its share count is up 33.69% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 24.70% below the market cap, as cash exceeds debt.
| Market Cap | $311.65M |
|---|---|
| Enterprise Value | $234.66M |
| Latest price (Nov 17, 2026) | $2.99 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 11.54% over 52 weeks and trades 3.10% above its 50-day average.
| Beta (1Y) | 1.91 |
|---|---|
| 52-Week Change | -11.54% |
| 1-Month Change | +41.04% |
| 3-Month Change | -29.65% |
| 6-Month Change | -10.21% |
| 5-Year Change | -79.33% |
| 10-Year Change | -93.16% |
| Total Return (1Y) | -11.54% |
| Total Return (3Y CAGR) | -3.14% |
| Total Return (5Y CAGR) | -21.96% |
| Return vs SPY (1Y) | -23.36% |
| Max Drawdown (1Y) | -66.64% |
| Max Drawdown (3Y) | -87.12% |
| Sharpe Ratio (1Y) | -0.14 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $2.90 |
| 200-Day Average | $3.76 |
| 52-Week Range | $1.92 to $6.42 |
| RSI (14 Days) | 58.6 |
| Average Volume (20 Days) | 1.35M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.82x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.82x |
|---|---|
| Quick Ratio | 3.82x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -153.77% over the last 12 months, against a 5-year average of -82.96%.
| Return on Equity (ROE) | -153.77% |
|---|---|
| Return on Assets (ROA) | -111.05% |
| Return on Capital Employed (ROCE) | -151.68% |
| ROE (5Y Average) | -82.96% |
| ROA (5Y Average) | -56.94% |
Scores
LRMR has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$87.00K |
| Operating Income | -$161.95M |
| Pretax Income | -$164.36M |
| Net Income | -$156.03M |
| EBITDA | -$159.92M |
| EBIT | -$159.05M |
| Reported EPS (TTM) | -$1.63 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.22% of the $140.50M in total assets.
| Cash and Equivalents | $76.99M |
|---|---|
| Total Debt | $0 |
| Net Cash | $76.99M |
| Net Cash Per Share | $0.74 |
| Working Capital | $100.51M |
| Shareholder Equity | $101.47M |
| Book Value Per Share | $0.97 |
| Total Assets | $140.50M |
| Total Liabilities | $39.04M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $158.00K of capital spending, operating cash flow left -$233.19M of free cash flow.
| Operating Cash Flow | -$233.03M |
|---|---|
| Capital Expenditures | $158.00K |
| Free Cash Flow | -$233.19M |
| FCF Per Share | -$2.24 |
| Depreciation and Amortization | $1.41M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
LRMR does not pay a dividend. Its free cash flow yield is -74.48%.
| FCF Yield | -74.48% |
|---|---|
| Buyback Yield | -35.30% |
| Shareholder Yield | -35.30% |
Stock Splits
The last split was a 1-for-12 reverse split on May 29, 2020.
| Last Split Date | May 29, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About LRMR
What is LRMR's market cap?
Larimar Therapeutics has a market cap of $311.65M. Its enterprise value, which adds debt and subtracts cash, is $234.66M.
How many shares of LRMR are outstanding?
Larimar Therapeutics has 104.71M shares outstanding. The count is up 33.69% from a year earlier.
Does LRMR pay a dividend?
No. Larimar Therapeutics does not pay a dividend.
How much debt does LRMR have?
Larimar Therapeutics has $0 of total debt and $76.99M of cash and equivalents, a net cash position of $76.99M.
LRMR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors